Literature DB >> 17322391

Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M.

Hiroshi Koyama1, Terumasa Hibi, Zenzo Isogai, Masahiko Yoneda, Minoru Fujimori, Jun Amano, Masatomo Kawakubo, Reiji Kannagi, Koji Kimata, Shun'ichiro Taniguchi, Naoki Itano.   

Abstract

Elevated concentrations of hyaluronan are often associated with human breast cancer malignancy. Here, we investigated the roles of hyaluronan in carcinogenesis and cancer progression using the mouse mammary tumor virus (MMTV)-Neu transgenic model of spontaneous breast cancer. Conditional transgenic mice that express murine hyaluronan synthase 2 (Has2) by Cre-mediated recombination were generated and crossed with the MMTV-Neu mice. In expressing Cre recombinase under the control of the MMTV promoter, the bigenic mice bearing Has2 and neu transgenes exhibited a deposition of hyaluronan matrix and aggressive growth of Neu-initiated mammary tumors. Notably, forced expression of Has2 impaired intercellular adhesion machinery and elicited cell survival signals in tumor cells. Concurrent with these alterations of tumor cells, intratumoral stroma and microvessels were markedly induced. To reveal the molecular basis of hyaluronan-mediated neovascularization, various hyaluronan samples were examined for their ability to potentiate in vivo angiogenesis. In Matrigel plug assays, basic fibroblast growth factor-induced neovascularization was elevated in the presence of either hyaluronan oligosaccharides or a hyaluronan aggregate containing versican. Administration of hyaluronan-versican aggregates, but not native hyaluronan alone, promoted stromal cell recruitment concurrently with the infiltration of endothelial cells. Taken together, these results suggest that hyaluronan overproduction accelerates tumor angiogenesis through stromal reaction, notably in the presence of versican.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17322391      PMCID: PMC1864876          DOI: 10.2353/ajpath.2007.060793

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  50 in total

1.  Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme.

Authors:  T D Camenisch; A P Spicer; T Brehm-Gibson; J Biesterfeldt; M L Augustine; A Calabro; S Kubalak; S E Klewer; J A McDonald
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  Inhibition of platelet-derived growth factor-BB-induced receptor activation and fibroblast migration by hyaluronan activation of CD44.

Authors:  Lingli Li; Carl-Henrik Heldin; Paraskevi Heldin
Journal:  J Biol Chem       Date:  2006-06-28       Impact factor: 5.157

3.  Involvement of endothelial CD44 during in vivo angiogenesis.

Authors:  Gaoyuan Cao; Rashmin C Savani; Melane Fehrenbach; Chris Lyons; Lin Zhang; George Coukos; Horace M Delisser
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

4.  Hyaluronan activates cell motility of v-Src-transformed cells via Ras-mitogen-activated protein kinase and phosphoinositide 3-kinase-Akt in a tumor-specific manner.

Authors:  Y Sohara; N Ishiguro; K Machida; H Kurata; A A Thant; T Senga; S Matsuda; K Kimata; H Iwata; M Hamaguchi
Journal:  Mol Biol Cell       Date:  2001-06       Impact factor: 4.138

Review 5.  Fibroblasts in cancer.

Authors:  Raghu Kalluri; Michael Zeisberg
Journal:  Nat Rev Cancer       Date:  2006-05       Impact factor: 60.716

6.  Proteoglycans of human umbilical cord arteries.

Authors:  T Gogiel; S Jaworski
Journal:  Acta Biochim Pol       Date:  2000       Impact factor: 2.149

7.  Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival.

Authors:  P Auvinen; R Tammi; J Parkkinen; M Tammi; U Agren; R Johansson; P Hirvikoski; M Eskelinen; V M Kosma
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

8.  Overexpression of hyaluronan synthase-2 reduces the tumorigenic potential of glioma cells lacking hyaluronidase activity.

Authors:  Bouchra Enegd; James A J King; Stan Stylli; Lucy Paradiso; Andrew H Kaye; Ulrike Novak
Journal:  Neurosurgery       Date:  2002-06       Impact factor: 4.654

Review 9.  Versican: a versatile extracellular matrix proteoglycan in cell biology.

Authors:  Thomas N Wight
Journal:  Curr Opin Cell Biol       Date:  2002-10       Impact factor: 8.382

10.  Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway.

Authors:  Shibnath Ghatak; Suniti Misra; Bryan P Toole
Journal:  J Biol Chem       Date:  2002-07-26       Impact factor: 5.157

View more
  69 in total

Review 1.  Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer.

Authors:  Ki Young Choi; Gurusamy Saravanakumar; Jae Hyung Park; Kinam Park
Journal:  Colloids Surf B Biointerfaces       Date:  2011-10-20       Impact factor: 5.268

2.  RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration.

Authors:  Neveen Said; Marta Sanchez-Carbayo; Steven C Smith; Dan Theodorescu
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

3.  Caution should be used in long-term treatment with oral compounds of hyaluronic acid in patients with a history of cancer.

Authors:  Procopio Simone; Migliore Alberto
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

4.  Developing vasculature and stroma in engineered human myocardium.

Authors:  Kareen L Kreutziger; Veronica Muskheli; Pamela Johnson; Kathleen Braun; Thomas N Wight; Charles E Murry
Journal:  Tissue Eng Part A       Date:  2011-02-02       Impact factor: 3.845

5.  Hyaluronan synthase 2 (HAS2) promotes breast cancer cell invasion by suppression of tissue metalloproteinase inhibitor 1 (TIMP-1).

Authors:  Berit Bernert; Helena Porsch; Paraskevi Heldin
Journal:  J Biol Chem       Date:  2011-10-20       Impact factor: 5.157

Review 6.  Hyaluronan-CD44 interactions as potential targets for cancer therapy.

Authors:  Suniti Misra; Paraskevi Heldin; Vincent C Hascall; Nikos K Karamanos; Spyros S Skandalis; Roger R Markwald; Shibnath Ghatak
Journal:  FEBS J       Date:  2011-03-25       Impact factor: 5.542

Review 7.  The evolving relationship of wound healing and tumor stroma.

Authors:  Deshka S Foster; R Ellen Jones; Ryan C Ransom; Michael T Longaker; Jeffrey A Norton
Journal:  JCI Insight       Date:  2018-09-20

8.  Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.

Authors:  Albert Lo; Liang-Chuan S Wang; Steven M Albelda; Ellen Puré; John Scholler; James Monslow; Diana Avery; Kheng Newick; Shaun O'Brien; Rebecca A Evans; David J Bajor; Cynthia Clendenin; Amy C Durham; Elizabeth L Buza; Robert H Vonderheide; Carl H June
Journal:  Cancer Res       Date:  2015-05-15       Impact factor: 12.701

9.  Hyaluronan Production Regulates Metabolic and Cancer Stem-like Properties of Breast Cancer Cells via Hexosamine Biosynthetic Pathway-coupled HIF-1 Signaling.

Authors:  Theerawut Chanmee; Pawared Ontong; Tomomi Izumikawa; Miho Higashide; Nobutoshi Mochizuki; Chatchadawalai Chokchaitaweesuk; Manatsanan Khansai; Kazuki Nakajima; Ikuko Kakizaki; Prachya Kongtawelert; Naoyuki Taniguchi; Naoki Itano
Journal:  J Biol Chem       Date:  2016-10-06       Impact factor: 5.157

10.  A case of cervical cancer expressed three mRNA variant of Hyaluronan-mediated motility receptor.

Authors:  Vanessa Villegas-Ruíz; Mauricio Salcedo; Alejandro Zentella-Dehesa; Edén V Montes de Oca; Edgar Román-Basaure; Alejandra Mantilla-Morales; Víctor M Dávila-Borja; Sergio Juárez-Méndez
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.